Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91
Non-small cell lung cancer (NSCLC) is among the most common types of cancer and contributes significantly to cancer-related mortality worldwide. Although some progress has been made in the treatment of NSCLC, drug resistance, high costs, and significant individual variability continue to be major ob...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1607264/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849390937295290368 |
|---|---|
| author | Lei Song Lei Song Jing Han Run Wang Shen Cao Yi Tai Xinyu Wang Yanjin Zheng Shufeng Jin Yiqian Shen Cai Qin Liu Yue Xing Hong Xiang Zuo Ming Yue Li Juan Ma Xuejun Jin |
| author_facet | Lei Song Lei Song Jing Han Run Wang Shen Cao Yi Tai Xinyu Wang Yanjin Zheng Shufeng Jin Yiqian Shen Cai Qin Liu Yue Xing Hong Xiang Zuo Ming Yue Li Juan Ma Xuejun Jin |
| author_sort | Lei Song |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is among the most common types of cancer and contributes significantly to cancer-related mortality worldwide. Although some progress has been made in the treatment of NSCLC, drug resistance, high costs, and significant individual variability continue to be major obstacles to effective treatment. Cucurbitacin B (CuB) is a tetracyclic triterpenoid known for its anti-inflammatory and anticancer properties. Previous studies have demonstrated that CuB plays a therapeutic role in NSCLC, however, the mechanism by which it acts necessitates additional research. We used network pharmacology and molecular docking to predict the targets of CuB in NSCLC. Western blot, RT-PCR, immunofluorescence, and co-immunoprecipitation assays were employed to assess the therapeutic effects of CuB on NSCLC in vitro, as well as to elucidate the specific mechanisms involved. Cell colony formation, EDU staining, angiogenesis, scratch assays, and invasion assays, were employed to evaluate the inhibitory effect of CuB on NSCLC. In vivo, C57BL/6 mice were subcutaneously injected with A549 cells to establish lung cancer xenograft models for evaluating the anticancer effects of CuB. Network pharmacology revealed that the primary target of CuB for NSCLC is HIF-1α. Molecular docking studies demonstrated that CuB exhibits strong binding affinity to both HIF-1α and ZFP91. In vitro experiments demonstrated that CuB inhibited HIF-1α expression via ZFP91. Additionally, CuB also suppressed HIF-1α through the Akt/mTOR/p70S6K signaling pathways. Further studies demonstrated that CuB inhibited cell proliferation, migration, invasion, and angiogenesis. In vivo animal experiments have further demonstrated that CuB exhibits a significant therapeutic effect on lung cancer models in mice. Our experiments demonstrated for the first time that CuB inhibits HIF-1α expression through ZFP91. This inhibition reduces the proliferation, migration, invasion, and angiogenesis of lung cancer cells associated with HIF-1α. Additionally, CuB regulates HIF-1α expression by inhibiting the Akt/mTOR/p70S6K signaling pathway. Our findings further elucidate the mechanism by which CuB acts in the treatment of lung cancer, providing a rationale for its development as a therapeutic option for NSCLC. |
| format | Article |
| id | doaj-art-06fde7e932cc433998bfc119fba4b95e |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-06fde7e932cc433998bfc119fba4b95e2025-08-20T03:41:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.16072641607264Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91Lei Song0Lei Song1Jing Han2Run Wang3Shen Cao4Yi Tai5Xinyu Wang6Yanjin Zheng7Shufeng Jin8Yiqian Shen9Cai Qin Liu10Yue Xing11Hong Xiang Zuo12Ming Yue Li13Juan Ma14Xuejun Jin15Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin, ChinaAffiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin, ChinaNon-small cell lung cancer (NSCLC) is among the most common types of cancer and contributes significantly to cancer-related mortality worldwide. Although some progress has been made in the treatment of NSCLC, drug resistance, high costs, and significant individual variability continue to be major obstacles to effective treatment. Cucurbitacin B (CuB) is a tetracyclic triterpenoid known for its anti-inflammatory and anticancer properties. Previous studies have demonstrated that CuB plays a therapeutic role in NSCLC, however, the mechanism by which it acts necessitates additional research. We used network pharmacology and molecular docking to predict the targets of CuB in NSCLC. Western blot, RT-PCR, immunofluorescence, and co-immunoprecipitation assays were employed to assess the therapeutic effects of CuB on NSCLC in vitro, as well as to elucidate the specific mechanisms involved. Cell colony formation, EDU staining, angiogenesis, scratch assays, and invasion assays, were employed to evaluate the inhibitory effect of CuB on NSCLC. In vivo, C57BL/6 mice were subcutaneously injected with A549 cells to establish lung cancer xenograft models for evaluating the anticancer effects of CuB. Network pharmacology revealed that the primary target of CuB for NSCLC is HIF-1α. Molecular docking studies demonstrated that CuB exhibits strong binding affinity to both HIF-1α and ZFP91. In vitro experiments demonstrated that CuB inhibited HIF-1α expression via ZFP91. Additionally, CuB also suppressed HIF-1α through the Akt/mTOR/p70S6K signaling pathways. Further studies demonstrated that CuB inhibited cell proliferation, migration, invasion, and angiogenesis. In vivo animal experiments have further demonstrated that CuB exhibits a significant therapeutic effect on lung cancer models in mice. Our experiments demonstrated for the first time that CuB inhibits HIF-1α expression through ZFP91. This inhibition reduces the proliferation, migration, invasion, and angiogenesis of lung cancer cells associated with HIF-1α. Additionally, CuB regulates HIF-1α expression by inhibiting the Akt/mTOR/p70S6K signaling pathway. Our findings further elucidate the mechanism by which CuB acts in the treatment of lung cancer, providing a rationale for its development as a therapeutic option for NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1607264/fullcucurbitacin Bnon-small cell lung cancerHIF-1αZFP91anti-cancer |
| spellingShingle | Lei Song Lei Song Jing Han Run Wang Shen Cao Yi Tai Xinyu Wang Yanjin Zheng Shufeng Jin Yiqian Shen Cai Qin Liu Yue Xing Hong Xiang Zuo Ming Yue Li Juan Ma Xuejun Jin Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91 Frontiers in Oncology cucurbitacin B non-small cell lung cancer HIF-1α ZFP91 anti-cancer |
| title | Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91 |
| title_full | Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91 |
| title_fullStr | Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91 |
| title_full_unstemmed | Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91 |
| title_short | Cucurbitacin B inhibits HIF-1α and attenuates non-small cell lung cancer via ZFP91 |
| title_sort | cucurbitacin b inhibits hif 1α and attenuates non small cell lung cancer via zfp91 |
| topic | cucurbitacin B non-small cell lung cancer HIF-1α ZFP91 anti-cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1607264/full |
| work_keys_str_mv | AT leisong cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT leisong cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT jinghan cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT runwang cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT shencao cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT yitai cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT xinyuwang cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT yanjinzheng cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT shufengjin cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT yiqianshen cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT caiqinliu cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT yuexing cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT hongxiangzuo cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT mingyueli cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT juanma cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 AT xuejunjin cucurbitacinbinhibitshif1aandattenuatesnonsmallcelllungcancerviazfp91 |